Trial Profile

The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients.

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Melatonin (Primary)
Indications Anxiety; Depressive disorders; Sleep disorders
Focus Therapeutic Use
Acronyms MELODY

Most Recent Events

06 May 2014 Biomarkers information updated
14 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
14 Dec 2012 Planned end date changed from 1 Jul 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com